CELGENE CORPORATION XBRL Taxonomy Presentation Networks

-Network: (00 - Document - Document and Company Information)
-Document And Entity Information [Abstract] {ID1}
Entity Registrant Name {ID2}
Entity Central Index Key {ID3}
Document Type {ID4}
Document Period End Date {ID5}
Amendment Flag {ID6}
Amendment Description {ID7}
Current Fiscal Year End Date {ID8}
Entity Well-known Seasoned Issuer {ID9}
Entity Voluntary Filers {ID10}
Entity Current Reporting Status {ID11}
Entity Filer Category {ID12}
Entity Public Float {ID13}
Entity Common Stock, Shares Outstanding {ID14}
-Network: (01 - Statement - Consolidated Statements of Operations)
-Statements Of Operations [Abstract] {ID15}
-Statement [Table] {ID16}
-Statement [Line Items] {ID17}
-Revenue: {ID18}
Net product sales {ID19}
Collaborative agreements and other revenue {ID20}
Royalty revenue {ID21}
Total revenue {ID22}
-Expenses: {ID23}
Cost of goods sold (excluding amortization of acquired intangible assets) {ID24}
Research and development {ID25}
Selling, general and administrative {ID26}
Amortization of acquired intangible assets {ID27}
Acquired in-process research and development {ID28}
Total expenses {ID29}
Operating income (loss) {ID30}
-Other income and expense: {ID31}
Interest and investment income, net {ID32}
Equity in (income) losses of affiliated companies {ID33}
Interest expense {ID34}
Other income, net {ID35}
Income (loss) before income taxes {ID36}
Income tax provision {ID37}
Net income (loss) {ID38}
-Net income (loss) per common share: {ID39}
Basic {ID40}
Diluted {ID41}
-Weighted average shares (in thousands): {ID42}
Basic {ID43}
Diluted {ID44}
-Network: (02 - Statement - Consolidated Balance Sheets)
-Balance Sheets [Abstract] {ID45}
-Statement [Table] {ID46}
-Statement [Line Items] {ID47}
-Assets {ID48}
-Current assets: {ID49}
Cash and cash equivalents {ID50}
Marketable securities available for sale {ID51}
Accounts receivable, net of allowances of $9,678 and $9,391 at June 30, 2009 and December 31, 2008, respectively {ID52}
Inventory {ID53}
Deferred income taxes {ID54}
Other current assets {ID55}
Total current assets {ID56}
Property, plant and equipment, net {ID57}
Investment in affiliated companies {ID58}
Intangible assets, net {ID59}
Goodwill {ID60}
Other assets {ID61}
Total assets {ID62}
-Liabilities and Stockholders' Equity {ID63}
-Current liabilities: {ID64}
Accounts payable {ID65}
Accrued expenses {ID66}
Income taxes payable {ID67}
Current portion of deferred revenue {ID68}
Other current liabilities {ID69}
Total current liabilities {ID70}
Deferred revenue, net of current portion {ID71}
Non-current income taxes payable {ID72}
Other non-current liabilities {ID73}
Total liabilities {ID74}
Commitments and Contingencies {ID75}
-Stockholders' Equity: {ID76}
Preferred stock, $.01 par value per share, 5,000,000 shares authorized; none outstanding at June 30, 2009 and December 31, 2008, respectively {ID77}
Common stock, $.01 par value per share, 575,000,000 shares authorized; issued 464,719,591 and 463,274,296 shares at June 30, 2009 and December 31, 2008, respectively {ID78}
Common stock in treasury, at cost; 6,198,012 and 4,144,667 shares at June 30, 2009 and December 31, 2008, respectively {ID79}
Additional paid-in capital {ID80}
Accumulated deficit {ID81}
Accumulated other comprehensive loss {ID82}
Total stockholders' equity {ID83}
Total liabilities and stockholders' equity {ID84}
-Network: (021 - Statement - Consolidated Balance Sheets (Parenthetical))
-Balance Sheets (Parenthetical) [Abstract] {ID85}
-Statement [Table] {ID86}
-Statement [Line Items] {ID87}
Allowances for accounts receivable {ID88}
Preferred stock, par value {ID89}
Preferred stock, shares authorized {ID90}
Preferred stock, shares outstanding {ID91}
Common stock, par value {ID92}
Common stock, shares authorized {ID93}
Common stock, shares issued {ID94}
Treasury shares, at cost {ID95}
-Network: (03 - Statement - Consolidated Statements of Cash Flows)
-Statements Of Cash Flows [Abstract] {ID96}
-Statement [Table] {ID97}
-Statement [Line Items] {ID98}
-Cash flows from operating activities: {ID99}
Net income (loss) {ID100}
-Adjustments to reconcile net income (loss) to net cash provided by operating activities: {ID101}
Depreciation of long-term assets {ID102}
Amortization of intangible assets {ID103}
Allocation of pre-paid royalties {ID104}
Provision for accounts receivable allowances {ID105}
Deferred income taxes {ID106}
Acquired in-process research and development {ID107}
Share-based compensation expense {ID108}
Equity in (income) losses of affiliated companies {ID109}
Share-based employee benefit plan expense {ID110}
Unrealized change in value of foreign currency forward contracts {ID111}
Realized gain on marketable securities available for sale {ID112}
Other, net {ID113}
-Change in current assets and liabilities, excluding the effect of acquisition: {ID114}
Accounts receivable {ID115}
Inventory {ID116}
Other operating assets {ID117}
Accounts payable and other operating liabilities {ID118}
Income tax payable {ID119}
Deferred revenue {ID120}
Net cash provided by operating activities {ID121}
-Cash flows from investing activities: {ID122}
Proceeds from sales of marketable securities available for sale {ID123}
Purchases of marketable securities available for sale {ID124}
Payments for acquisition of business, net of cash acquired {ID125}
Capital expenditures {ID126}
Investment in affiliated companies {ID127}
Purchases of investment securities {ID128}
Other {ID129}
Net cash used in investing activities {ID130}
-Cash flows from financing activities: {ID131}
Payment for treasury shares {ID132}
Net proceeds from exercise of common stock options and warrants {ID133}
Excess tax benefit from share-based compensation arrangements {ID134}
Net cash provided by (used in) financing activities {ID135}
Effect of currency rate changes on cash and cash equivalents {ID136}
Net increase (decrease) in cash and cash equivalents {ID137}
Cash and cash equivalents at beginning of period {ID138}
Cash and cash equivalents at end of period {ID139}
-Supplemental schedule of non-cash investing and financing activity: {ID140}
Change in net unrealized (gain) loss on marketable securities available for sale {ID141}
Matured shares tendered in connection with stock option exercises {ID142}
Conversion of convertible notes {ID143}
-Supplemental disclosure of cash flow information: {ID144}
Interest paid {ID145}
Income taxes paid {ID146}
-Network: (04 - Statement - Consolidated Statements of Stockholders Equity)
-Statements Of Stockholders Equity [Abstract] {ID147}
-Statement [Table] {ID148}
-Statement [Line Items] {ID149}
Beginning Balance {ID150}
-Other comprehensive income: {ID151}
Increase in unrealized gain on available for sale securities, net of tax of $5,211, $29,631 and $6,013 for 2008, 2007 and 2006 respectively {ID152}
Reversal of unrealized gains on Pharmion investment, net of tax of $38,904 {ID153}
Reclassification adjustment for losses included in net income (loss), net of tax of $736, $3,860 and $4,062 for 2008, 2007 and 2006 respectively {ID154}
Unrealized losses on cash flow hedges {ID155}
Pension liability adjustment {ID156}
Net asset transfer of common control foreign subsidiaries {ID157}
Currency translation adjustments {ID158}
Comprehensive income (loss) {ID159}
Treasury stock -mature shares tendered related to option exercise {ID160}
Issuance of common stock related to the 2:1 February 17, 2006 stock split {ID161}
Costs related to 2006 secondary stock offering {ID162}
Acquisition of Pharmion Corp. {ID163}
Conversion of long-term convertible notes {ID164}
Issuance of common stock related to the secondary stock offering {ID165}
Exercise of stock options and warrants {ID166}
Issuance of common stock for employee benefit plans {ID167}
Issuance of restricted stock {ID168}
Expense related to stock-based compensation {ID169}
Expense related to stock-based compensation and restricted stock granted to employees {ID170}
Income tax benefit upon exercise of stock options {ID171}
Ending Balance {ID172}
-Statement, Equity Components [Axis] {ID173}
-Equity Component [Domain] {ID174}
-Parent [Member] {ID175}
Common Stock {ID176}
Preferred Stock [Member] {ID177}
Capital Units [Member] {ID178}
Common Stock Including Additional Paid in Capital [Member] {ID179}
Preferred Stock Including Additional Paid in Capital [Member] {ID180}
-Additional Paid-in Capital {ID181}
Other Additional Capital [Member] {ID182}
Deferred Compensation, Share-based Payments [Member] {ID183}
Treasury Stock {ID184}
-Retained Earnings (Deficit) {ID185}
Retained Earnings, Appropriated [Member] {ID186}
Retained Earnings, Unappropriated [Member] {ID187}
Undistributed Income from Other than Gain or Loss on Sale of Properties [Member] {ID188}
Undistributed Net Realized Gain or Loss on Sale of Properties [Member] {ID189}
Accumulated Distributions in Excess of Net Income [Member] {ID190}
-Accumulated Other Comprehensive Income (Loss) {ID191}
Accumulated Net Unrealized Investment Gain (Loss) [Member] {ID192}
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] {ID193}
Accumulated Translation Adjustment [Member] {ID194}
Accumulated Defined Benefit Plans Adjustment [Member] {ID195}
Noncontrolling Interest [Member] {ID196}
Comprehensive Income [Member] {ID197}
-Network: (041 - Statement - Consolidated Statements of Stockholders Equity (Parenthetical))
-Statement Of Stockholders Equity (Parenthetical) [Abstract] {ID198}
-Statement [Table] {ID199}
-Statement [Line Items] {ID200}
Tax effect on increase in unrealized gain on available for sale securities {ID201}
Tax effect on reversal of unrealized gains on Pharmion investment {ID202}
Tax effect on reclassification adjustment for losses included in net income (loss) {ID203}
-Statement, Equity Components [Axis] {ID204}
-Equity Component [Domain] {ID205}
-Parent [Member] {ID206}
Common Stock {ID207}
Preferred Stock [Member] {ID208}
Capital Units [Member] {ID209}
Common Stock Including Additional Paid in Capital [Member] {ID210}
Preferred Stock Including Additional Paid in Capital [Member] {ID211}
-Additional Paid-in Capital {ID212}
Other Additional Capital [Member] {ID213}
Deferred Compensation, Share-based Payments [Member] {ID214}
Treasury Stock {ID215}
-Retained Earnings (Deficit) {ID216}
Retained Earnings, Appropriated [Member] {ID217}
Retained Earnings, Unappropriated [Member] {ID218}
Undistributed Income from Other than Gain or Loss on Sale of Properties [Member] {ID219}
Undistributed Net Realized Gain or Loss on Sale of Properties [Member] {ID220}
Accumulated Distributions in Excess of Net Income [Member] {ID221}
-Accumulated Other Comprehensive Income (Loss) {ID222}
Accumulated Net Unrealized Investment Gain (Loss) [Member] {ID223}
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member] {ID224}
Accumulated Translation Adjustment [Member] {ID225}
Accumulated Defined Benefit Plans Adjustment [Member] {ID226}
Noncontrolling Interest [Member] {ID227}
Comprehensive Income [Member] {ID228}
-Network: (0601 - Disclosure - Nature of Business and Basis of Presentation)
-Nature Of Business And Basis Of Presentation [Abstract] {ID229}
Nature Of Business And Basis Of Presentation {ID230}
-Network: (0602 - Disclosure - Summary of Significant Accounting Policies)
-Summary Of Significant Accounting Policies [Abstract] {ID231}
Summary of Significant Accounting Policies {ID232}
-Network: (0603 - Disclosure - Acquisition of Pharmion Corporation)
-Acquisition Of Business [Abstract] {ID233}
Acquisition of Pharmion Corporation {ID234}
-Network: (0604 - Disclosure - Restructuring)
-Restructuring [Abstract] {ID235}
Restructuring {ID236}
-Network: (0605 - Disclosure - Earnings Per Share (EPS))
-Earnings Per Share Disclosure [Abstract] {ID237}
Earnings Per Share (EPS) {ID238}
-Network: (0606 - Disclosure - Comprehensive Income (Loss))
-Comprehensive Income (Loss) [Abstract] {ID239}
Comprehensive Income (Loss) {ID240}
-Network: (0607 - Disclosure - Financial Instruments and Fair Value Measurement)
-Financial Instruments And Fair Value Measurement [Abstract] {ID241}
Financial Instruments and Fair Value Measurement {ID242}
-Network: (0608 - Disclosure - Derivative Instruments And Hedging Activities)
-Derivative Instruments And Hedging Activities [Abstract] {ID243}
Derivative Instruments and Hedging Activities {ID244}
-Network: (0609 - Disclosure - Cash, Cash Equivalents and Marketable Securities Available for Sale)
-Cash, Cash Equivalents And Marketable Securities Available-For-Sale [Abstract] {ID245}
Cash, Cash Equivalents and Marketable Securities Available-for-Sale {ID246}
-Network: (0610 - Disclosure - Inventory)
-Inventory [Abstract] {ID247}
Inventory {ID248}
-Network: (0611 - Disclosure - Investment in Affiliated Companies)
-Investment In Affiliated Companies [Abstract] {ID249}
Investment in Affiliated Companies {ID250}
-Network: (0612 - Disclosure - Intangible Assets and Goodwill)
-Intangible Assets and Goodwill [Abstract] {ID251}
Intangible Assets and Goodwill {ID252}
-Network: (0613 - Disclosure - Share Based Compensation)
-Share Based Compensation Disclosure [Abstract] {ID253}
Share-Based Compensation {ID254}
-Network: (0614 - Disclosure - Income Taxes)
-Income Taxes [Abstract] {ID255}
Income Taxes {ID256}
-Network: (0615 - Disclosure - Collaboration Agreements)
-Collaboration Agreements [Abstract] {ID257}
Collaboration Agreements {ID258}
-Network: (0616 - Disclosure - Commitments and Contingencies)
-Commitments and Contingencies [Abstract] {ID259}
Commitments and Contingencies {ID260}
-Network: (0617 - Disclosure - Subsequent Event)
-Subsequent Event [Abstract] {ID261}
Subsequent Event {ID262}